Systematic review of tumour budding and association with common mutations in patients with colorectal cancer

[Display omitted] •Meta-analysis evaluated relationship between mutated KRAS/BRAF or MSI tumour and tumour budding in colorectal cancer patients.•17 potential studies were included in this review.•Mutated KRAS and MSS/pMMR tumour significantly associated with high-grade budding phenotype. Despite a...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2021-11, Vol.167, p.103490-103490, Article 103490
Main Authors: Hatthakarnkul, Phimmada, Quinn, Jean A., Matly, Amna Ahmed Mohemmd, Ammar, Aula, van Wyk, Hester C., McMillan, Donald C., Edwards, Joanne
Format: Article
Language:English
Subjects:
Colorectal cancer
KRAF/BRAF mutation
MSS/pMMR tumour
Systematic review
Tumour budding
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Meta-analysis evaluated relationship between mutated KRAS/BRAF or MSI tumour and tumour budding in colorectal cancer patients.•17 potential studies were included in this review.•Mutated KRAS and MSS/pMMR tumour significantly associated with high-grade budding phenotype. Despite a well-known prognostic role in colorectal cancer, the genomic profiling of tumour budding remains to be elucidated. We aim to review the association of common mutations with tumour budding. A systematic review of studies relating to tumour budding and genetic mutation in CRC was performed. The relationship between mutational status and tumour budding was evaluated using meta-analysis. A total of 6153 patients from 17 articles were included. According to the meta-analysis, high-grade tumour budding was significantly associated with KRAS mutation (OR = 1.52, 95 %CI: 1.13–2.02, P = 0.005) and MSS/pMMR (OR = 2.06, 95 %CI: 1.42–2.97, P = 0.0001). The significant association between high-grade tumour budding and mutated KRAS or MSS/pMMR may suggest a role of these mutations in the development of the tumour budding phenotype and be useful for stratifying patient outcome in CRC.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2021.103490